Boston Scientific Downgraded by Citi on 'Uncertain Recovery Path'

Citi has downgraded Boston Scientific (NYSE: BSX) to Neutral from Buy, signaling diminished confidence in the medical device maker's near-term prospects. Analyst Joanne Wuensch also cut the firm's price target on the stock to $50 from $57, citing an "uncertain recovery path" following a string of operational and market challenges this year.

A More Cautious Stance

In a note published September 17, Wuensch stated that Boston Scientific's fortunes have "shifted in a big way" in 2026. The firm highlighted that it has lowered its estimates for the company eight times this year, undermining the stock's long-standing reputation for consistent "beat-and-raise" performance.

The analyst wrote that the "time to resolution is opaque, investor patience has run thin," and Citi does not "have a handle on the recovery path." This uncertainty prompted the move to the sidelines until a clearer picture emerges.

Multiple Headwinds Pressure Growth

Citi's downgrade is based on several distinct headwinds impacting key business segments. The analyst noted that confidence in a swift recovery is low, particularly as the effects of a recent cybersecurity attack could be "protracted."

Ad

Key challenges outlined in the report include:

• A more mature and competitive U.S. market for pulsed field ablation (PFA) technology.
• A stagnating market for its left atrial appendage closure (LAAC) devices.
• Unspecified "hiccups" in its urology division.
• The lingering impact of a recent cybersecurity attack.

Product-Specific Challenges

For the company's Watchman LAAC device, Citi flagged proposed new guidelines and pending reimbursement changes that could negatively affect uptake. Boston Scientific's management has guided for the overall closure market to decline in the second half of 2026 and into 2027, with the company also expected to lose some market share to Abbott's next-generation Amulet device.

In electrophysiology, the note stated that competition in PFA is expected to remain a headwind for Boston Scientific's Farapulse system until new catheters are launched, which is not anticipated until the second half of 2027. Reflecting this pressure, Citi now models Farapulse-related sales to fall 5.3% in the second half of 2026 and remain flat in 2027.